Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide Dose Optimization in Elderly Patients With Advanced Prostate Cancer
NCT07512076Phase 2Not yet recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Apr 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in prostate cancer (PCa), sponsored by Sunnybrook Health Sciences Centre. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07512076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07512076.